

III. REMARKS

Claims 66-130 are pending.

Description of Amendments

Claim 80 has been amended to remove the following compounds:

- 3-bromo-5-fluoro- α , β , β -dimethyl-4-[3-(2-pyridinylamino)propoxy]-benzene butanoic acid;
- 3-fluoro- β , β -dimethyl-4-[3-(2-pyridinylamino)propoxy]benzene-butanoic acid;
- 3-chloro- β , β -dimethyl-4-[3-(2-pyridinylamino)propoxy]benzene-butanoic acid;
- β -methyl- β -[[4-[3-(2-pyridinylamino)propoxy]phenyl]methyl]-3-pyridine propanoic acid;
- 3-methoxy- β , β -dimethyl-4-[3-(2-pyridinylamino)propoxy]benzene-butanoic acid;


Applicants submit that these compounds were not part of original claim 13, on which claim 80 is based, and were inadvertently included.

Claims 109-112 have been amended to change the phrase " $\alpha_v\beta_s$ mediated" to " $\alpha_v\beta_s$ integrin mediated"

It is therefore submitted that Claims 66-130 are in condition for allowance.

If the Office has any further comments or concerns, the Examiner is welcome to contact Applicants at the number below.

Respectfully submitted,



Rachel A. Polster

Registration No. 47,004

Telephone: 314-274-7354

Pfizer Corporation
Global Patent Department
P.O. Box 1027
St. Louis, MO 63006